. 2021 Mar 29;12:657768. doi: 10.3389/fimmu.2021.657768

Table 5.

DC-based tolerogenic vaccines.

DC-Based Tolerogenic Vaccines	Prophylactic Vaccination			Therapeutic Vaccination			Bystander/Infectious Tolerance	Proposed Mechanism of Action	Ref.
	Route	Days	EAE Model	Route	Days	EAE Model
Andrographolide or rosiglitazone treated DCs loaded with MOG_35-55	IV	-7 and -14	C57BL/6 with MOG_35-55	N/A	N/A	N/A	N/A	Andrographolide or rosiglitazone treated DCs had reduced expression of CD40 and CD86. When loaded with MOG_35-55 the DCs increased FOXP3 mRNA expression in spleen, decreased MOG-specific antibodies, and decreased MOG_35-55 specific T cell production of INF-γ and IL-2 and suppress EAE.	(190)
Tofacitinib treated DCs loaded with MOG_35-55	N/A	N/A	N/A	IV	7, 11 and 15	C57BL/6 with MOG_35-55	N/A	Tofacitinib treated DCs exhibited reduced expression of CD80, CD86, CD83, CD40, IL-1, IL-6, IL-12, IL-23, and TNF-α. When loaded with MOG_35-55 the DCs reduced the percentage of IL-17⁺ and IFN-γ ⁺ T cells, increased the percentage of Tregs in spleen and ameliorated EAE.	(191)
BD750 treated DCs loaded with MOG_35-55	N/A	N/A	N/A	IV	7, 11 and 15	C57BL/6 with MOG_35-55	N/A	BD750 treated DCs exhibited reduced expression of CD80, CD86, CD83 and CD40. When loaded with MOG_35-55 the DCs reduced the frequency of Th1 and Th17, increased the percentage of Tregs in spleen and suppressed EAE.	(192)
Dexamethasone and/or minocycline treated DCs loaded with MOG_35-55	IV	-7 and -3	C57BL/6 with MOG_35-55	N/A	N/A	N/A	N/A	Dexamethasone and/or minocycline treated DCs exhibited reduced levels of MCHII, CD80, CD86, TNF-α, IL-1β, IL-6, and IL-12 and increased levels of PDL-1, ICOSL and IL-10 and induced Tregs in vitro. When loaded with MOG_35-55 these DCs suppressed EAE.	(193)
VitD3 treated DCs loaded with MOG_35-55	N/A	N/A	N/A	IV	10, 13 and 16	C57BL/6 with MOG_35-55	N/A	VitD3 treated DCs exhibited reduced levels of MHCII, CD80, and CD83. When loaded with MOG_35-55 these DCs reduced Th1 and Th17 cells infiltration into spinal cord, increased the percentage of Tregs in spleen and lymph node, increased the number of Bregs in spleen and suppressed EAE.	(194)
Il-27 treated DCs loaded with PLP_139-151	N/A	N/A	N/A	IV	20, 24, 28 and 32	SJL with PLP_139-151	Maybe	IL-27 treated DCs exhibited reduced levels of MHCII, CD40, CD80, CD86, IL-6, IL-12 and IL-23, increased levels of TGF-β, IL-10 and IFN-β, induced Tregs and Tr1 cells. When loaded with PLP_139-151 the DCs suppressed EAE and PLP_178-191 T cell responses.	(195)
IL-10 and LPS treated DCs loaded with MOG_35-55	IV	-21	C57BL/6 with MOG_35-55	N/A	N/A	N/A	N/A	IL-10 and LPS treated DCs exhibited decreased IL-12 production and impaired antigen-specific T cell proliferation in vitro When loaded with MOG_35-55 these DCs suppressed EAE.	(196)